Objectives: Allogeneic hematopoietic stem cell transplantation (HSCT) effectively treats high-risk myeloid neoplasms, but relapses post-HSCT, particularly in acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), pose significant challenges. Donor lymphocyte infusion (DLI) has been utilized, but its effectiveness, especially in haploidentical settings, remains insufficiently clarified, and graft-versus-host disease (GvHD) poses a substantial risk.
Methods: In this retrospective cohort study, 57 patients with AML or MDS who received DLI after allogeneic HSCT at our center from 2002 to 2023 were analyzed. Herein, only preemptively or therapeutically applied DLI were included, and endpoints included overall survival (OS), progression-free survival (PFS), and GvHD incidence post-DLI.
Results: Median OS after DLI was 517 days, with a 1-year OS of 62.5%. Factors associated with longer OS included patient age, HLA-identical donor, post-HSCT treatment naivety, and preemptive DLI indication. Haploidentical DLI was associated with inferior OS compared to HLA-identical DLI; however, PFS and GvHD incidence post-DLI did not differ significantly.
Conclusions: Our study findings indicate that OS rate is inferior in patients with relapsed AML or MDS treated with haploidentical DLI in comparison to those who received HLA-identical DLI. Given the limitations of haploidentical DLI, alternative strategies, such as higher cell doses or combination treatment approaches, warrant further investigation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707813 | PMC |
| http://dx.doi.org/10.1111/ejh.14340 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation.
Transplant Cell Ther
January 2025
Azienda Sanitaria Universitaria Friuli Centrale, DMED, University of Udine, Udine, Italy.
Article Synopsis
- Allogeneic stem cell transplantation (allo-SCT) offers curative potential for multiple myeloma patients but is effective in only a minority, with some patients experiencing long-term survival after relapse thanks to a combination of antimyeloma drugs and donor T cells.
- A study evaluating 242 multiple myeloma patients who underwent allo-SCT revealed a median overall survival of 39.4 months and highlighted factors like older age and previous therapies that predict shorter survival outcomes.
- Among 118 relapsed patients, various treatments were employed, with a significant portion receiving multiple lines of salvage therapy, including chemotherapy and immunomodulating agents, demonstrating a diverse treatment approach post-relapse.
Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.
Eur J Haematol
February 2025
Department of Medical Oncology and Hematology, University Hospital Zurich, Zürich, Switzerland.
Objectives: Allogeneic hematopoietic stem cell transplantation (HSCT) effectively treats high-risk myeloid neoplasms, but relapses post-HSCT, particularly in acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), pose significant challenges. Donor lymphocyte infusion (DLI) has been utilized, but its effectiveness, especially in haploidentical settings, remains insufficiently clarified, and graft-versus-host disease (GvHD) poses a substantial risk.
Methods: In this retrospective cohort study, 57 patients with AML or MDS who received DLI after allogeneic HSCT at our center from 2002 to 2023 were analyzed.
Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.
Cancer Lett
November 2024
Peking University People's Hospital & Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, PR China; Peking-Tsinghua Center for Life Sciences, Beijing, PR China; State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, PR China. Electronic address:
Article Synopsis
- In 2018, the Chinese Society of Haematology established guidelines for monitoring and treating leukaemia relapse after stem cell transplantation, enhancing China's clinical practices and global integration.
- Recently, experts updated the consensus to include a strategy focused on measurable residual disease (MRD) and improved therapies, emphasizing haploidentical HSCT for high-risk patients.
- The updated guidelines promote advancements in MRD detection methods and explore new targeted treatment options, underscoring a significant progression in managing post-transplant leukaemia relapses.
Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report.
Front Immunol
March 2024
Division of Hematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programmed cell death protein-1 (PD-1) blocking agents have demonstrated clinical activity with durable responses in relapsed/refractory (r/r) HL. However, patients with a history of allo-HSCT were frequently excluded from clinical trials due to concerns about the risk of graft-versus-host disease (GVHD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!